Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 601–700 of 1,000
Induced Pluripotent Stem Cell Technology for Generating Photoreceptors
Boucherie, C., Sowden, J. C., & Ali, R. R. (2011) · Regenerative Medicine · doi:10.2217/rme.11.37 · Cited by 28
New approaches for the generation of induced pluripotent stem cells
Sidhu, K. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.558837 · Cited by 31
“Current reports using iPSC to model genetic diseases like spinal muscular atrophy and familial dysautonomia have shown disease-specific phenotypes that may be important for modelling and drug discovery [48,49].”
BackgroundMori, E., Fujikura, J., Noguchi, M., Nakao, K., Matsubara, M., Sone, M., Taura, D., Kusakabe, T., Ebihara, K., Tanaka, T., et al. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.015 · Cited by 28
“[15] Ebert AD, Yu J, Rose Jr FF, et al.”
BackgroundGeneration and validation of PAX7 reporter lines from human iPS cells using CRISPR/Cas9 technology
Wu, J., Hunt, S. D., Xue, H., Liu, Y., & Darabi, R. (2016) · Stem Cell Research · doi:10.1016/j.scr.2016.01.003 · Cited by 29
Min, Z., Gao, Q., Zhen, X., Fan, Y., Tan, T., Li, R., Zhao, Y., & Yu, Y. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0950-x · Cited by 29
Spinal Cord Organoids to Study Motor Neuron Development and Disease
Buchner, F., Dokuzluoglu, Z., Graß, T., & Rodríguez‐Muela, N. (2023) · Life · doi:10.3390/life13061254 · Cited by 32
Multipotent Progenitor Cells in Regenerative Cardiovascular Medicine
Lam, J. T., Moretti, A., & Laugwitz, K. (2009) · Pediatric Cardiology · doi:10.1007/s00246-009-9450-1 · Cited by 31
“Recent reports have illustrated examples of establishing iPS cells from skin fibroblasts of an 82-year-old woman with amyotrophic lateral sclerosis, a child with spinal muscular atrophy, and patients with a variety of both simple and complex genetic disorders [14, 15, 42].”
BackgroundAutologous cell therapy for cardiac repair
Davis, D. R., & Stewart, D. J. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.556615 · Cited by 34
Tracking gene and cell fate for therapeutic gain
Kooreman, N. G., Ransohoff, J. D., & Wu, J. C. (2014) · Nature Materials · doi:10.1038/nmat3868 · Cited by 28
Human Kidney Cell Reprogramming: Applications for Disease Modeling and Personalized Medicine
O’Neill, A. C., & Ricardo, S. D. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121199 · Cited by 29
Rowntree, R. K., & McNeish, J. D. (2010) · Regenerative Medicine · doi:10.2217/rme.10.36 · Cited by 29
Hosoya, M., & Czysz, K. (2016) · Cells · doi:10.3390/cells5040046 · Cited by 27
“Shortly thereafter, the strategy to recapitulate disease phenotypes by using patient-derived iPS cells was applied to mimic spinal muscular atrophy (SMA) [39] and familial dysautonomia [40].”
BackgroundJaiswal, M. K. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.206635 · Cited by 31
“Until Ebert and Svendsen first established human derived iPSCs recapitulating the MND and SMA pathology (Ebert et al., 2009), only models utilized to study SMA were worms and rodents posing serious limitation in terms of detailed understanding of human pathology in the context of these diseases.”
BackgroundMethodInfluentialAndo, S., Funato, M., Ohuchi, K., Kameyama, T., Inagaki, S., Seki, J., Kawase, C., Tsuruma, K., Shimazawa, M., Kaneko, H., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.005 · Cited by 28
Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis
Ziff, O. J., & Patani, R. (2018) · Aging Cell · doi:10.1111/acel.12862 · Cited by 29
Characterization of Human iPSC-derived Spinal Motor Neurons by Single-cell RNA Sequencing
Thiry, L., Hamel, R., Pluchino, S., Durcan, T. M., & Stifani, S. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.041 · Cited by 30
Induced Pluripotent Stem Cells to Model and Treat Neurogenetic Disorders
Wang, H., & Doering, L. C. (2012) · Neural Plasticity · doi:10.1155/2012/346053 · Cited by 34
“Taken together, these studies show that human iPSCs are useful to model the specific neuronal pathology of SMA and human iPSCs represent a promising resource to screen new drug compounds and develop new therapies for SMA [98].”
BackgroundInfluentialThiry, L., Clément, J.-P., Haag, R., Kennedy, T. E., & Stifani, S. (2022) · ASN NEURO · doi:10.1177/17590914211073381 · Cited by 26
A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance
Engeholm, M., Sekler, J., Schöndorf, D. C., Arora, V., Schittenhelm, J., Biskup, S., Schell, C., & Gasser, T. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-118 · Cited by 33
“The use of patient-derived induced pluripotent stem cells [21], which can be differentiated into motor neurons [22], will offer the opportunity to study these processes in a more authentic context than previous cell culture experiments.”
BackgroundModeling Long-QT Syndromes with iPS Cells
Sinnecker, D., Goedel, A., Dorn, T., Dirschinger, R. J., Moretti, A., & Laugwitz, K. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9416-1 · Cited by 27
“While the first diseases analyzed by this novel technology were neurodegenerative [4,16] and hematological [30] disorders, the application to the in-”
BackgroundInduced pluripotent stem cells as a next-generation biomedical interface
Hankowski, K. E., Hamazaki, T., Umezawa, A., & Terada, N. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.85 · Cited by 30
Farokhpour, M., Karbalaie, K., Tanhaei, S., Nematollahi, M., Etebari, M., Hamid, M., Nasr‐Esfahani, M. H., & Baharvand, H. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.07.008 · Cited by 28
Vaskova, E. A., Medvedev, S. P., Sorokina, A. E., Nemudryi, A. A., Elisaphenko, E. A., Zakharova, I. S., Shevchenko, A. I., Kizilova, E. A., Zhelezova, A. I., Evshin, I. S., et al. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0204 · Cited by 26
Paré, B., Touzel‐Deschênes, L., Pouliot, R., Dupré, N., & Gros‐Louis, F. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00070 · Cited by 30
Zhang, Q., Li, J.-J., Lin, X., Lu, Y., Guo, X.-X., Dong, E., Zhao, M., He, J., Wang, N., & Chen, W. (2017) · Oncotarget · doi:10.18632/oncotarget.14641 · Cited by 28
“Recently, with the development of cell reprogramming technology, induced pluripotent stem cells (iPSs), which are reprogrammed from adult somatic cells via the overexpression of defined transcription factors, open a new and effective avenue for the generation of induced motor neurons in vitro [2-3].”
BackgroundRecapitulating and Correcting Marfan Syndrome in a Cellular Model
Park, J. W., Li, Y., Stoddard, C., Wang, X., Yue, Z., Crandall, L. J., Robinson, T. M., Chang, Y., Denton, K. R., Li, E., et al. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19517 · Cited by 30
“Patient-derived induced pluripotent stem cells (iPSCs) have offered unprecedented opportunities to model [14-16] and genetically treat diseases [17-20].”
BackgroundGiorgio, M. L. D., Esposito, A., Maccallini, P., Micheli, E., Bavasso, F., Gallotta, I., Vernì, F., Feiguin, F. M., Cacchione, S., McCabe, B. D., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.005 · Cited by 28
“SMN also prevents accumulation of RNA–DNA hybrids, which is thought to result in DNA damage and apoptosis (ANDERTON et al. 2013; ZHAO et al. 2016), and is required for maintenance of embryonic stem cells and neuronal differentiation (EBERT et al. 2009; CHANG et al. 2015).”
BackgroundGray, K. M., Kaifer, K. A., Baillat, D., Wen, Y., Bonacci, T., Ebert, A. D., Raimer, A. C., Spring, A. M., ten Have, S., Glascock, J., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-11-0627 · Cited by 31
“Aggregates were passaged using a manual chopping technique as previously described (Svendsen et al., 1998; Ebert et al., 2013).”
MethodSelf-citationLodola, F., Vurro, V., Crasto, S., Pasquale, E. D., & Lanzani, G. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900198 · Cited by 28
Darabi, R., & Perlingeiro, R. C. R. (2014) · Methods in molecular biology · doi:10.1007/7651_2014_134 · Cited by 29
Understanding and Modulating Immunity With Cell Reprogramming
Pires, C. F., Rosa, F. A., Kurochkin, I., & Pereira, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02809 · Cited by 30
Toward pluripotency by reprogramming: mechanisms and application
Wang, T., Warren, S. T., & Jin, P. (2013) · Protein & Cell · doi:10.1007/s13238-013-3074-1 · Cited by 30
“, 2008), and spinal muscular atrophy (Ebert et al., 2009).”
Therapeutic developments in spinal muscular atrophy
Sproule, D. M., & Kaufmann, P. (2010) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610369026 · Cited by 26
“Induced pluripotent stem cells have been derived from patients with SMA and used to generate motor neurons that show selective deficits compared with wild-type motor neurons in culture [Ebert et al. 2009].”
Stem cell-based strategies for the treatment of type 1 diabetes mellitus
Wen, Y., Chen, B., & Ildstad, S. T. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540235 · Cited by 29
“Recently, disease-specific iPSC have been generated from a wide variety of adult somatic cell types from donors with various disease conditions, including T1D, to fulfill therapeutic applications [35-42].”
Epigenetics of induced pluripotency, the seven-headed dragon
Djuric, U., & Ellis, J. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt3 · Cited by 28
“Several of these studies demonstrated directed iPS cell diff erentiation to aff ected cell types with Ebert and colleagues [44] and Lee and colleagues [42] reporting the fi rst successful phenotype improvements using a chemical treatment.”
BackgroundInduced pluripotent stem cells and their implication for regenerative medicine
Csöbönyeiová, M., Polák, Š., Koller, J., & Danišovič, Ľ. (2014) · Cell and Tissue Banking · doi:10.1007/s10561-014-9462-9 · Cited by 30
The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside
Xie, N., & Tang, B. (2016) · Stem Cells International · doi:10.1155/2016/6484713 · Cited by 27
“Similar screening platforms have also been applied in other neurological diseases, such as familial dysautonomia [52] and spinal muscular atrophy (SMA) type I [53].”
Gene therapy for amyotrophic lateral sclerosis
Federici, T., & Boulis, N. M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.018 · Cited by 28
Cell reprogramming: methods, mechanisms and applications
Zhu, F., & Nie, G. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00229-x · Cited by 28
Lall, D., Workman, M. J., Sances, S., Ondatje, B. N., Bell, S., Lawless, G. M., Woodbury, A., West, D., Meyer, A. S., Matlock, A. D., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.015 · Cited by 32
Self-citationZhang, W., Jiao, B., Zhou, M., Zhou, T., & Shen, L. H. (2016) · Stem Cells International · doi:10.1155/2016/7828049 · Cited by 30
“These disorders include, among others, Parkinson’s disease (PD) with SNCA, PINK1, PARK2, GBA1, and LRRK2 mutations [68–70], amyotrophic lateral sclerosis (ALS) with TDP43 mutation [71], Huntington’s disease (HD) with HTT mutation [72], and Spinal muscular atrophy (SMA) with SMN1 mutation [73].”
Nathamgari, S. S. P., Pathak, N., Lemaitre, V., Mukherjee, P., Muldoon, J. J., Peng, C., McGuire, T. L., Leonard, J. N., Kessler, J. A., & Espinosa, H. D. (2020) · Small · doi:10.1002/smll.202002616 · Cited by 24
Welby, E., Rehborg, R., Harmelink, M. M., & Ebert, A. D. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab365 · Cited by 27
Self-citationInduced pluripotent stem cells in research and therapy.
Teoh, H.-K., & Cheong, S. (2012) · PubMed · Cited by 29
Stem cell therapies for recessive dystrophic epidermolysis bullosa
Petrova, A., Ilić, D., & McGrath, J. A. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.09981.x · Cited by 27
Stem cell repair of striatal ischemia
Kokaia, Z., & Lindvall, O. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59544-7.00003-2 · Cited by 30
Implications of aneuploidy for stem cell biology and brain therapeutics
Devalle, S., Sartore, R., Paulsen, B. S., Borges, H. L., Martins, R. A. P., & Rehen, S. K. (2012) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2012.00036 · Cited by 27
“…loxapine administration (Brennand et al., 2011); motor neurons differentiated from spinal muscular atrophy’s iPSCs had diminished expression of full length SMN-RNA, and the accumulation of SMN nuclear aggregates could be observed after exposure to valproic acid and tobramycin (Ebert et al., 2009).”
BackgroundXie, Y., & Zhang, R. X. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1989-9 · Cited by 29
“Excitingly, the administration of valproic acid and tobramycin could reverse the endogenous SMN protein level in differentiated neurons and astrocytes [51].”
BackgroundKhalifian, S., Sarhane, K. A., Tammia, M., Ibrahim, Z., Mao, H., Cooney, D. S., Shores, J. T., Lee, W. P. A., & Brandacher, G. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0323-9 · Cited by 27
“…Stem Cells Recent advances in induced pluripotent stem (iPS) cell research and technology have enabled the generation of patient-specific cell lines that may be utilized as a therapeutic modality in various disorders (Dimos et al. 2008; Ebert et al. 2009; Lee et al. 2009; Park et al. 2008).”
BackgroundNuclear Reprogramming Strategy Modulates Differentiation Potential of Induced Pluripotent Stem Cells
Martinez‐Fernandez, A., Nelson, T. J., & Terzic, A. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9250-2 · Cited by 31
“iPS cells have been generated from both genetic and noninheritable diseases, including Parkinson’s disease, Duchenne muscular dystrophy, Becker’s muscular dystrophy, Down’s syndrome, Huntington’s disease [49], myeloproliferative disorders [50], amyotrophic lateral sclerosis [51], Fanconi’s anemia [52], type 1 diabetes…”
BackgroundStem Cells in Drug Screening for Neurodegenerative Disease
Kim, H., & Jin, C. Y. (2012) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2012.16.1.1 · Cited by 24
“Furthermore iPSCs were generated from fibroblasts taken from patients suffering from neurodegenerative diseases [52,53,113].”
BackgroundInfluentialMomčilović, O., Sivapatham, R., Oron, T. R., Meyer, M., Mooney, S. D., Rao, M. S., & Zeng, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154890 · Cited by 25
Promise of Retinoic Acid-Triazolyl Derivatives in Promoting Differentiation of Neuroblastoma Cells
Lone, A. M., Dar, N. J., Hamid, A., Shah, W. A., Ahmad, M., & Bhat, B. A. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00267 · Cited by 26
Vila, O. F., Qu, Y., & Vunjak‐Novakovic, G. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1700225 · Cited by 25
Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises
Argentati, C., Tortorella, I., Bazzucchi, M., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10010008 · Cited by 25
“Spinal muscular atrophy Patient-derived fibroblasts [76]”
In Vitro Uses of Human Pluripotent Stem Cell-Derived Cardiomyocytes
Matsa, E., & Denning, C. N. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9376-5 · Cited by 26
Lin, X., Li, J.-J., Qian, W., Zhang, Q., Wang, Z., Lu, Y., Dong, E., He, J., Wang, N., Ma, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14925 · Cited by 27
“Briefly, the cell line was derived from SMA type I patient’s fibroblasts by reprogramming with lentiviral constructs encoding OCT4, SOX2, NANOG and LIN28 [10].”
MethodModeling heart disease in a dish: From somatic cells to disease-relevant cardiomyocytes
Zanella, F., Lyon, R. C., & Sheikh, F. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2013.06.002 · Cited by 25
Paulsen, B. D. S., Silveira, M. S., Galina, A., & Rehen, S. K. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.10.009 · Cited by 25
Feeder-free Derivation of Neural Crest Progenitor Cells from Human Pluripotent Stem Cells
Zeltner, N., Lafaille, F. G., Fattahi, F., & Studer, L. (2014) · Journal of Visualized Experiments · doi:10.3791/51609 · Cited by 24
Mack, D. L., Guan, X., Wagoner, A. L., Walker, S. J., & Childers, M. K. (2014) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000000141 · Cited by 25
Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges
Israel, M. A., & Goldstein, L. S. B. (2011) · Genome Medicine · doi:10.1186/gm265 · Cited by 24
“[59] were the first to report a phenotype in vitro when they demonstrated the partial modeling of spinal muscular atrophy (SMA) type I.”
BackgroundCell models and drug discovery for mitochondrial diseases
Hu, S., Zhuang, Q., Qiu, Y., Zhu, X., & Yan, Q. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900196 · Cited by 23
Multiple sclerosis: getting personal with induced pluripotent stem cells
Ruscio, A. D., Patti, F., Welner, R. S., Tenen, D. G., & Amabile, G. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.179 · Cited by 24
“However,motor neuronswere selectively lost in theneural culture recapitulating the patient-specific SMA phenotype.(64) Interest-”
Cellular reprogramming: a new approach to modelling Parkinson's disease
Hartfield, E. M., Fernandes, H. J. R., Vowles, J., Cowley, S. A., & Wade‐Martins, R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120159 · Cited by 26
Murata, M., Tohyama, S., & Fukuda, K. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.010 · Cited by 27
Winner, B., Marchetto, M. C., Winkler, J., & Gage, F. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu205 · Cited by 25
“Motor neuron disease modeling using iPSC Disease Gene mutation or sporadic Number of patients/ controls Type of neuron investigated Neuronal phenotype observed in vitro Correction in vitro References HSP SPG4, Spastin 2/2 1/1 Forebrain neuron Neurite swellings, altered axonal transport Overexpression of Spastin rescue…”
BackgroundInfluentialConcise Review: Pluripotent Stem Cell-Based Regenerative Applications for Failing β-Cell Function
Holditch, S. J., Terzic, A., & Ikeda, Y. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0184 · Cited by 26
CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish
Gonzãlez, F. (2016) · Developmental Dynamics · doi:10.1002/dvdy.24414 · Cited by 24
“For example, a progressive loss of motor neurons is observed when spinal muscular atrophy hiPSCs are differentiated toward the neural lineage, possibly mirroring the loss of motor neurons observed in the patients (Ebert et al., 2009).”
BackgroundAddressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies
Dashtban, M., Panchalingam, K. M., Shafa, M., & Ahmadian Baghbaderani, B. (2020) · Methods in Molecular Biology · doi:10.1007/7651_2020_288 · Cited by 17
Induced Pluripotent Stem Cells and Periodontal Regeneration
Du, M., Duan, X., & Yang, P. (2015) · Current Oral Health Reports · doi:10.1007/s40496-015-0065-8 · Cited by 26
Schuster, J., Halvardson, J., Lorenzo, L. P. E., Ameur, A., Sobol, M., Raykova, D., Annerén, G., Feuk, L., & Dahl, N. (2015) · Cellular Reprogramming · doi:10.1089/cell.2015.0009 · Cited by 22
“Thus, research using iPSCs has provided an invaluable tool for in vitro disease modeling, biomarker identification, drug discovery, toxicity studies, and cell replacement therapy (Ebert et al., 2009; Kondo et al., 2013; Soldner et al., 2009).”
Instant Neurons: Directed Somatic Cell Reprogramming Models of Central Nervous System Disorders
Liang, Q., Inoue, K., & Abeliovich, A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.027 · Cited by 23
Parkinson's Disease: From Genetics to Treatments
Fan, H., Chen, S., Harn, H., & Lin, S. (2013) · Cell Transplantation · doi:10.3727/096368912x655082 · Cited by 26
Hardingham, G. E., Patani, R., Baxter, P. S., Wyllie, D. J. A., & Chandran, S. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8136-2 · Cited by 23
“Compared with a wild-type iPS cell line, SMAiPS cells were equally amenable to differentiation into immature motor neurons, but numbers of motor neurons observed at later timepoints post-differentiation were much reduced in the SMA-iPS cell cultures, compared with wildtype, indicative of either impaired production or…”
BackgroundResultHein, N. D., Rainier, S. R., Richardson, R. J., & Fink, J. K. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.06.020 · Cited by 22
Song, M., Paul, S., Lim, H., Dayem, A. A., & Cho, S. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0205-9 · Cited by 23
“In a study of a neurological disease, motor neurons were generated from a spinal muscular atrophy (SMA) patient (Ebert et al., 2009).”
BackgroundMaking neurons from mature glia: A far-fetched dream?
Berninger, B. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.004 · Cited by 26
“These protocols should in principle also work for induced pluripotent stem cells (iPSCs) (Dimos et al., 2008; Ebert et al., 2009; Wernig et al., 2008), i.”
Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
Tsai, L. (2012) · Neural Plasticity · doi:10.1155/2012/456478 · Cited by 23
“Recently, iPS cells have been successfully generated from fibroblasts of SMA patients [162, 163].”
BackgroundEnvironmental epigenetic modifications and reprogramming-recalcitrant genes
Sakurada, K. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.01.001 · Cited by 24
Generation and genetic modification of induced pluripotent stem cells
Schambach, A., Cantz, T., Baum, C., & Cathomen, T. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.496775 · Cited by 26
“Some protocols for differentiation of human iPSCs into several different cell types are available, such as blood cells [115,116], motor neurons [117,118], dopaminergic neurons [54], retinal cells [119], hepatocytes [120] and many other cell types.”
BackgroundDick, E., Matsa, E., Bispham, J., Reza, M., Guglieri, M., Staniforth, A., Watson, S., Kumari, R., Lochmüller, H., Young, L. E., et al. (2010) · Stem Cell Research · doi:10.1016/j.scr.2010.10.002 · Cited by 25
Pluripotent Human Stem Cells: A Novel Tool in Drug Discovery
Phillips, B. W., & Crook, J. M. (2010) · BioDrugs · doi:10.2165/11532270-000000000-00000 · Cited by 25
“Examples include trisomy 21, Huntington disease, amyotrophic lateral sclerosis, Gaucher disease, Duchenne muscular dystrophy, and type 1 diabetes, among others,([33,34,81,82]) with POC for drug screening applications provided using spinal muscular atrophy (SMA)([83]) and familial dysautonomia([84]) cell lines.”
BackgroundInfluentialGeneration of Human Melanocytes from Induced Pluripotent Stem Cells
Ohta, S., Imaizumi, Y., Akamatsu, W., Okano, H., & Kawakami, Y. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-330-5_16 · Cited by 24
Liu, Y., Lu, S., & Yao, J. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12528 · Cited by 22
“In 2009, the first iPSC-based study for a neuronal disorder was carried out for spinal muscular atrophy (SMA).(7) In the same year, an iPSC model of familial dysautonomia was established, for the first time, to validate candidate drugs.”
BackgroundChanging Fate: Reprogramming Cells via Engineered Nanoscale Delivery Materials
Dehnavi, S. S., Zadeh, Z. E., Harvey, A. R., Voelcker, N. H., Parish, C. L., Williams, R. J., Elnathan, R., & Nisbet, D. R. (2022) · Advanced Materials · doi:10.1002/adma.202108757 · Cited by 26
Sanjurjo‐Rodríguez, C., Castro-Viñuelas, R., Piñeiro-Ramil, M., Rodríguez-Fernández, S., Fuentes-Boquete, I. M., Blanco, F. J., & Díaz‐Prado, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176124 · Cited by 23
“Since isolated primary cells cannot be long-term maintained or expanded under conventional culture conditions, immortalized clonal cell lines are a frequently used cell source [16,20,21].”
BackgroundInduced Pluripotent Stem Cells for Tissue-Engineered Skeletal Muscles
Zhao, S., Chen, J., Wu, L., Tao, X., Yaqub, N., & Chang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411520 · Cited by 26
“iPSCs possess crucial characteristics, including pluripotency, allowing them to differentiate into various cell types found in the body, such as neurons [5], cardiovascular and hematopoietic lineages [6], cardio myocytes [7], and myogenic precursors [8].”
BackgroundShevde, N. K. (2012) · Nature · doi:10.1038/483s22a · Cited by 21
Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes
Upadhyay, G., Shankar, S., & Srivastava, R. K. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8883-6 · Cited by 23
Gene therapy for β-thalassaemia: the continuing challenge
Yannaki, E., Emery, D. W., & Stamatoyannopoulos, G. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001626 · Cited by 24
Generating Diverse Spinal Motor Neuron Subtypes from Human Pluripotent Stem Cells
Patani, R. (2015) · Stem Cells International · doi:10.1155/2016/1036974 · Cited by 25
“The fact that clinical neurodegenerative disease classically occurs in a region-specific and/or subtype-specific manner reinforces the importance of this line of enquiry.”
Transflammation: Innate immune signaling in nuclear reprogramming
Meng, S., Chanda, P. K., Thandavarayan, R. A., & Cooke, J. P. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.010 · Cited by 23
Giadone, R. M., Rosarda, J. D., Akepati, P. R., Thomas, A. C., Boldbaatar, B., James, M. F., Wilson, A. A., Sanchorawala, V., Connors, L. H., Berk, J. L., et al. (2018) · Amyloid · doi:10.1080/13506129.2018.1489228 · Cited by 21
“Recently, iPSCs have been used to model diseases as well as screen drugs for the treatment of amyotrophic lateral sclerosis [27], spinal muscular atrophy [18], long QT syndrome [28], familial dysautonomia [29], and familial TTR-amyloidosis [13].”
MethodHuman neurons to model aging: A dish best served old
Böhnke, L., Traxler, L., Herdy, J. R., & Mertens, J. (2018) · Drug Discovery Today: Disease Models · doi:10.1016/j.ddmod.2019.01.001 · Cited by 20
Induced Pluripotent Stem Cells: Characteristics and Perspectives
Cantz, T., & Martin, U. (2010) · Springer eBooks · doi:10.1007/10_2010_74 · Cited by 26
“described the generation of disease-specific iPS cells from patients’ skin fibroblast and compared these cells with iPS cells derived from fibroblasts of the unaffected mothers [99].”
ResultWang, N., Xu, Y., Qin, T., Wang, F.-P., Ma, L., Luo, X., & Zhang, T. (2013) · Gene · doi:10.1016/j.gene.2013.03.043 · Cited by 22
“…neural differentiation of several types of stem cells, including embryonic stem cells (ES) (Erceg et al., 2010), induced pluripotent stem (iPS) (Ebert et al., 2009), neural progenitor cells (Rasmussen et al., 2011), MSCs (Anghileri et al., 2008), et al. However, themechanismbywhichRA…”
BackgroundYoung, W. (2012) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.s10-010 · Cited by 24
“Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, et al. (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.”
BackgroundInfluentialMeasuring Circadian Clock Function in Human Cells
Gaspar, L., & Brown, S. A. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2014.10.023 · Cited by 23
“Recent studies demonstrated that the recapitulation of in vitro disease phenotype via iPSCs seems to be feasible for numerous monogenic diseases (Carvajal-Vergara et al., 2010; Ebert et al., 2009; Lee et al., 2009; Rashid et al., 2010; Urbach, Bar-Nur, Daley, & Benvenisty, 2010; Zhang et al., 2011).”
BackgroundGao, A., Peng, Y., Deng, Y., & Qing, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.076 · Cited by 24
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.